GRI: GRI Bio Corp Price-to-Revenue Multiple
GRI Bio, Inc. (GRI) is actively developing NKT cell modulators for the therapy of organ fibrosis. This GURU.Markets terminal chart of historical P/S dynamics reflects market sentiment, with the metric fixed at 0.00. Patents and the success of the GRI-0621 candidate are driving the stock's growth. Future profits are expected from the implementation of high-cost innovations for insurance funds and medical centers.
Analytical breakdowns for GRI Bio Corp (GRI)
- current quotes and average value forecast:
- market capitalization information:
- book capitalization data:
- issuer credit burden and liquidity indicators:
- earnings and valuation multiples information:
GRI - Net Profit|Company Profit Forecast GRI Bio, Inc.|GRI - Price to Earnings Ratio|Price to Future Earnings Ratio GRI Bio Inc|GRI - PEG Multiple|Enterprise Value to EBITDA Ratio GRI Bio Corp|GRI - Operating profit before deduction of amortization|Net earnings per share for the last four quarters GRI Bio|GRI - Net earnings per share (EPS TTM)|Net earnings per share growth for the trailing year gribio.com|GRI - Earnings per share growth in current year|Expected earnings per share trend next year GRI Bio, Inc.
- issuer revenue and sales details:
General company analysis:GRI, gribio.com
GRI Bio, Inc. is developing innovative immunology amidst geopolitical barriers that complicate biomaterial logistics and slow down global drug certification. The market capitalization-to-sales ratio allows for an assessment of the fundamental link between the share price and actual revenue, while the price/sales ratio trend helps investors timely recognize asset overbought conditions or the risk of capital freeze in a weakening business.
Competitors of GRI Bio, Inc.
ARGX - Price to Sales|P/S Multiple BNTX (BioNTech)|Price-to-Revenue Multiple Abivax Pharma|ADMA - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio PTGX (Protagonist Corp)|IMVT: P/S Multiple|KNSA - Price-to-Revenue Coefficient|Market Cap to Revenue GRFS|ADPT: Market Capitalization-to-Revenue Ratio|P/S Multiple CLDX|Price-to-Revenue Ratio AUPH (Aurinia Corp)|P/S Multiple BCRX (BioCryst)|Price-to-Revenue Coefficient veratx.com (VERA)|DNTH - Price-to-Revenue Ratio|Price to Sales Pharvaris NV|ABCL (AbCellera Biologics Inc) - Market Cap to Revenue|Tourmaline - Market Capitalization-to-Revenue Ratio|PGEN (Precigen, Inc.) - P/S Multiple|pharming.com (PHAR) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Nektar Therapeutics Inc. (NKTR)|Upstream Bio, Inc. - Market Cap to Revenue Ratio|P/S Multiple ZBIO (Zenas Biopharma, Inc.)|IMNM - Market Cap to Revenue|GOSS: Market Cap to Revenue|Price-to-Revenue Coefficient kalvista.com KALV|SEPN: P/S Multiple|Price-to-Revenue Multiple Pieris Pharma PVLA|Price-to-Revenue Ratio Savara Corp|RIGL: Market Capitalization-to-Revenue Ratio|P/S Multiple ANAB|Price-to-Revenue Coefficient astriatx.com|Price-to-Revenue Ratio enGene ENGN|RAPT (RAPT Therapeutics Inc.) - Price-to-Sales Ratio|Aerovate - P/S Multiple|Market Capitalization-to-Revenue Ratio ACRS (Aclaris Therapeutics, Inc)|KYTX: P/S Multiple|tizianalifesciences.com (TLSA) - P/S Multiple|Price-to-Revenue Ratio Cabaletta Bio|VTYX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Theratechnologies Inc (THTX)|Market Cap to Revenue Avalo Therapeutics Inc AVTX|P/S Multiple ELDN (Eledon Pharmaceuticals)|P/S Multiple agenusbio.com AGEN|CLYM: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio ZURA (Zura Bio Ltd)|ATYR: P/S Multiple|ADAG - Price-to-Revenue Coefficient|Price-to-Revenue Ratio ImageneBio|Market Cap to Revenue Shattuck Therapeutics (STTK)|Price-to-Revenue Ratio Equillium, Inc. (EQ)|Market Cap to Revenue connectbiopharm.com CNTB|Immunic - Market Cap to Revenue|P/S Multiple Atara Biotherapeutics, Inc. ATRA|IFRX - Price-to-Revenue Ratio|XFOR (x4pharma.com) - Market Cap to Revenue Ratio|ACET: P/S Multiple|Price to Sales Celularity (CELU)|INMB (INmune Bio Corp) - P/S Multiple|BRNS - Price-to-Revenue Multiple|Price-to-Revenue Ratio Kezar Life Sciences (KZR)|SABS (sabbiotherapeutics.com) - Market Capitalization-to-Revenue Ratio|P/S Multiple AKTX (Akari Therapeutics Plc)|Price-to-Revenue Coefficient Enlivex Therapeutics Ltd (ENLV)|QTTB: Market Cap to Revenue|Market Capitalization-to-Revenue Ratio GOVX (GeoVax Corp)|EDSA: P/S Multiple|IBIO (ibioinc.com) - Price-to-Revenue Ratio|CARM (Carisma Therapeutics Inc) - P/S Multiple|XTL Biopharmaceuticals Ltd (XTLB) - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Bolt Biotherapeutics (BOLT)|HCWB - Price to Sales|Aptevo Therapeutics Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio AIM|Aditxt Corp - P/S Multiple|Price-to-Revenue Coefficient XORTX Therapeutics Inc XRTX|ReShape Lifesciences (HIND) - Price-to-Revenue Ratio|Market Cap to Revenue Ratio REVB|INDP (Indaptus Therapeutics) - P/S Multiple|Market Cap to Revenue scinai.com (SCNI)|Market Cap to Revenue CALI (CalciMedica, Inc.)|Price-to-Revenue Coefficient affimed.com|P/S Multiple ALLK (Allakos)|Price-to-Revenue Multiple HOOKIPA Pharma, Inc.|IGMS - Price-to-Revenue Ratio|Market Capitalization-to-Revenue Ratio ITOS (iteostherapeutics.com)|OCEA: P/S Multiple|TCBP - Price-to-Revenue Coefficient|Price-to-Revenue Ratio Third Harmonic Bio, Inc
